Influenza, COVID-19, and RSV Immunization for 2026–27 Season
- Q: What’s new about 2026–27 season influenza vaccines and recommendations?
- Q: Where can I obtain seasonal influenza vaccine recommendations and clinical guidance for the 2026–27 season?
- Q: What is mFlusiva influenza vaccine, how well does it work, and who is it recommended for?
- Q: For which vaccines is an egg allergy a contraindication?
- Q: When administering influenza vaccine, is giving patients a vaccine information statement (VIS) mandatory or is it only “recommended”?
- Q: Can the new American Academy of Pediatrics (AAP) one-page immunization fact sheets for families be used instead of a VIS?
- Q: What are the 2026–27 season recommendations for COVID-19 vaccination from the major medical societies and how do they compare to CDC’s recommendations in 2025–26?
- Q: How long do I need to wait after giving a dose of a 2025–2026 Formula COVID-19 vaccine before I can administer a dose of the 2026–2027 Formula COVID-19 vaccine?
- Q: Which children age 8 through 19 months should receive a dose of RSV preventive antibody (nirsevimab) entering their second RSV season, according to the American Academy of Pediatrics?
- Q: Should an infant who received a birth dose of nirsevimab at the end of the RSV season in late March get another dose of nirsevimab or clesrovimab in October since they are still younger than 8 months of age?